Immunological Basis for Mepolizumab Activity in COPD
NCT05320939
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
COPD
Interventions
DRUG:
Mepolizumab 100 MG
Sponsor
Temple University
Collaborators
[object Object]